- $1.53bn
- $1.24bn
- $747.41m
- 74
- 65
- 94
- 92
Annual income statement for HCI, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Premiums Earned | |||||
Net Investment Income | |||||
Realized & Unrealized Gains / Losses | |||||
Total Revenue | 273 | 407 | 507 | 547 | 747 |
Losses, Benefits, and Adjustments | |||||
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 262 | 390 | 560 | 422 | 563 |
Operating Profit | 11 | 16.3 | -53.5 | 126 | 184 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 36.9 | 11.2 | -68.4 | 118 | 173 |
Provision for Income Taxes | |||||
Net Income After Taxes | 27.6 | 7.24 | -54.6 | 89.3 | 128 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 27.6 | 1.86 | -58.5 | 79 | 110 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 33.8 | 1.83 | -55 | 76.4 | 113 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.66 | 0.215 | -6.08 | 6.92 | 8.89 |
Dividends per Share |